Sign In
Buy RCEL
$4.16
-0.0300 (-0.716%)
At Close: Jun 03, 2026
AVITA Therapeutics, Inc. Announces Executive Change
10:30pm, Thursday, 05'th Nov 2020
VALENCIA, Calif. and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a
Avita Therapeutics, Inc. Announces Correction of Time for the Adjourned 2020 Annual Stockholder Meeting
07:46am, Thursday, 05'th Nov 2020
VALENCIA, Calif, and MELBOURNE, Australia, Nov. 05, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a
AVITA Therapeutics Announces Date Change for First Quarter 2021 Earnings Release and Conference Call
04:01pm, Tuesday, 03'rd Nov 2020
VALENCIA, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
AVITA Therapeutics, Inc. Announces Adjournment of 2020 Annual Stockholder Meeting
07:29pm, Thursday, 29'th Oct 2020
VALENCIA, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
AVITA Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 28'th Oct 2020
VALENCIA, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
AVITA Therapeutics to Announce First Quarter 2021 Financial Results
04:01pm, Tuesday, 27'th Oct 2020
VALENCIA, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that
